Please login to the form below

Not currently logged in
Email:
Password:

IMI picks Ipsen's Marc de Garidel to chair governing board

He takes over from former UCB CEO Roch Doliveux

Ipsen Marc de Garidel IMI Innovative Medicines InitiativeThe Innovative Medicines Initiative (IMI) has picked Ipsen's Marc de Garidel to take over as chair of its governing board from Roch Doliveux, who retired as CEO of UCB at the end of 2014.

De Garidel has been chairman and CEO of Ipsen, which specialises in neurology, endocrinology and urology-oncology, since 2010 and he chaired the European Biopharmaceutical Enterprises Association from 2010-12.

Prior to joining Ipsen he served as general manager of Amgen's French affiliate and before Amgen he held various, mainly financial roles, at Lilly.

Commenting on his appointment to the IMI de Garidel said: “I am honoured to represent the healthcare industry in the biggest public-private partnership in life sciences in Europe to date and I am convinced the IMI 2 has a real potential to tackle Europe's growing health challenges and deliver innovation for patients by working together and building on previous successes.”

The IMI is a public-private partnership between the European Union and European pharma body EFPIA and its governing board is the IMI's main decision-making body. Its second-phase IMI 2 programme aims to develop next generation vaccines, medicines and treatments, such as new antibiotics.

Irene Norstedt, IMI acting executive director, said: “IMI is delighted to welcome Marc de Garidel as chair of the governing board. I am confident that his decades of experience working in the pharmaceutical sector will prove invaluable to IMI.”

27th March 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Numbers, navigation, and narratives: digital storytelling in medical communications
Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
Is this common data mistake killing your digital patient recruitment?
Without realising, you could be falling into the trap of using social data — insights into recent, relevant trends and topics — to inspire your content. Hold up. That sounds...
Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...